Literature DB >> 1446953

Creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) activity in serum before and after intravenous salbutamol administration of patients with bronchial asthma.

R Chazan1, W Tadeusiak, A Jaworski, W Droszcz.   

Abstract

The effect of salbutamol, a selective beta 2-adrenergic agonist, on creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) activity in serum of 20 asthmatic patients was investigated. Venous blood was obtained 30 min, 2 h and 4 h after 0.5 mg salbutamol intravenous injection of 0.5 mg salbutamol. Total creatine kinase activity was assayed on a Technico RA-1000 analyzer with the IFCC recommended method. CK-MB activity was determined using a centrifugal analyzer (Cobas Fera, Roche, Switzerland). Reagent kits were provided by Boehringer Mannheim (FRG). We observed no increase of CK-activity after salbutamol, and found a statistically significant increase of CK-MB activity. Serum CK-MB activity before treatment was 13 +/- 10/IU/l after 30 minutes drug, 31.8 +/- 19 IU/l after 2 h 27.2 +/- 17.79 and after 4 h 22.6 +/- 12 IU/l. We conclude that salbutamol exerts a cardiotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446953

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  2 in total

1.  The dose-related hyper-and-hypokalaemic effects of salbutamol and its arrhythmogenic potential.

Authors:  W J Du Plooy; L Hay; C P Kahler; P J Schutte; H D Brandt
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

2.  Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.

Authors:  Maren Freigang; Claudia D Wurster; Tim Hagenacker; Benjamin Stolte; Markus Weiler; Christoph Kamm; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Alexander Kowski; Thomas Meyer; Jan C Koch; Isabell Cordts; Marcus Deschauer; Paul Lingor; Elisa Aust; Daniel Petzold; Albert C Ludolph; Björn Falkenburger; Andreas Hermann; René Günther
Journal:  Ann Clin Transl Neurol       Date:  2021-03-31       Impact factor: 4.511

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.